SCHEMBL6508991

SCHEMBL6508991

CCOc1ccc2[nH]c(=O)c3c(C)n(C4CCCCO4)nc3c2c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.44
KDM4E B2RXH2 12/20 0.41
HSD17B10 Q99714 8/20 0.41
ALDH1A1 P00352 7/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
TSHR P16473 1/20 0.41
HPGD P15428 6/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 3/20 0.40
ESR2 Q92731 1/20 0.40
ALOX5 P09917 1/20 0.37
GAA P10253 3/20 0.37
TYMS P04818 1/20 0.37
GLA P06280 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PKM P14618 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6529957 0.90 PARP1 (0.37) PARP1KDM4EALDH1A1
SCHEMBL6512957 0.84 KDM4E (0.43) KDM4EHSD17B10ALDH1A1HPGDPOLB
SCHEMBL6046806 0.84 IDH1 (0.36) KDM4EALDH1A1GAATYMS
SCHEMBL6508753 0.84 CHEK1 (0.47) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL6523130 0.82 ATR (0.44)
SCHEMBL6510968 0.81 DRD1 (0.33) PARP1
SCHEMBL6511000 0.80 PTGS2 (0.46) PARP1ALDH1A1MEN1KMT2APOLB
SCHEMBL6510843 0.78 CHEK1 (0.47) PARP1ALDH1A1MEN1KMT2ATP53
SCHEMBL6522020 0.76 CHEK1 (0.43) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL6515300 0.75 CHEK1 (0.39) KDM4EHSD17B10ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 PARP1 1091/4885KDM4E 1251/4885HSD17B10 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.